Search research articles
Contact Us
Filters
Showing results (221-230 of 271) with videos related to
Page
of 28
Sort By:
Journal for Immunotherapy of Cancer
|
October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal for Immunotherapy of Cancer
|
January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D Lewis, Harriet Kluger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis
Glenn Geidel, Sabrina Bänsch, Laura Adam, et al.
The New England Journal of Medicine
|
October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Briana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
Cancers
|
April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
Peter Mohr, Emilie Scherrer, Chalid Assaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Page
of 28
Search research articles
Search
Showing results (221-230 of 271) with videos related to
Sort By:
Page
of 28
Journal for Immunotherapy of Cancer
|
October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal for Immunotherapy of Cancer
|
January 5, 2023
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D Lewis, Harriet Kluger, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis
Glenn Geidel, Sabrina Bänsch, Laura Adam, et al.
The New England Journal of Medicine
|
October 9, 2016
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Briana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
Cancers
|
April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
Peter Mohr, Emilie Scherrer, Chalid Assaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
Caroline Robert, Georgina V Long, Benjamin Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Page
of 28